559results about "X-ray constrast preparations" patented technology

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

The invention discloses a medical developing marker and a manufacturing method thereof, and relates to the field of medical instruments, the medical developing marker comprises a closed tube, the outer wall of the closed tube is provided with a bionic barb structure, the bionic barb structure is distributed in a flexible zigzag convex manner, and the bionic barb structure and the closed tube are integrally formed through an injection molding process; a closed cavity is arranged in the closed tube, four developing strips are symmetrically arranged in the tube wall of the closed cavity, the tube wall of the region where the developing strips are located is etched to form a weak band, and a developing material layer and a sustained-release medicine layer are sequentially deposited at the weak band. The developing material layer and the sustained-release drug and / or marked nano-particle layer are alternately deposited to form a functional composite layer, and the functional composite layer can directionally rupture to release the therapeutic drug under the action of implantation pressure. The marker integrates the functions of precise development, tissue anchoring and drug sustained release, is adaptive to multi-mode imaging such as ultrasonic imaging, X-ray imaging, CT imaging, MRI imaging and PET-CT imaging, and has remarkable clinical value in precise positioning treatment of solid tumors such as breast cancer and liver cancer.

The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor.

The present invention relates to magnetic, catalytically active, and radiosensitizing nanoparticles (NanoXcats) and the method for their production. A method is disclosed for the production of functionalized greigite nanoparticles with a narrowband size distribution (10-30 nm) for use in multimodal cancer therapy. NanoXcats are superparamagnetic Fe3S4 nanoparticles whose surfaces are equipped with polar functional groups. The surface structures of NanoXcats are suitable for conjugation with, or for covalent or electrostatic binding of, active substances, which may be cancer drugs, cell growth inhibitors, or NO donors. Due to the EPR effect, NanoXcats are preferentially internalized by tumor cells. The targeted accumulation of NanoXcats in tumor tissue is achieved by an external inhomogeneous magnetic field. NanoXcats exhibit enhanced catalytic activity in tumor cells.The catalytic activity of intracellular NanoXcats can be triggered, controlled, and enhanced by low-dose X-rays. Surface-bound drugs are additionally activated in tumor cells by the catalytic activity of NanoXcats. NanoXcats act as superoxide dismutase, nitric oxide synthase, and Fenton catalyst. They catalyze, for example, reactions of the superoxide anion radical to hydrogen peroxide, of L-arginine to NO, and of hydrogen peroxide to the hydroxyl radical.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The present invention relates to the nanoparticles (NP) of the invention, compositions thereof and their use as therapeutic agents, in particular in the field of oncology and / or as imaging agents. The NPs consist of first nanoparticles of at least one high-Z metal oxide material, to which smaller second nanoparticles are covalently bonded at the surface of the first nanoparticles. The second nanoparticles consist of a) at least one noble metal or at least one metal oxide, metal sulfide, metal selenide or metal sulfide / selenide as a Fenton or Fenton-like reaction catalyst. The NPs of the invention produce a surprising therapeutic effect when exposed to ionizing radiation such as X-rays, gamma-rays, protons, neutrons, radioisotopes and / or electron beams. Therefore, these NPs can be used as radiosensitizers in the field of oncology. These nanoparticles can also be used as contrast agents.

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

The invention discloses a radionuclide-labeled collagen hybrid peptide probe as well as a preparation method and application thereof. The chemical structural general formula of the radionuclide-labeled collagen hybrid peptide probe is (metal nuclide-chelating agent)-Linker-CHP, wherein the metal nuclide is selected from any one of Al18F, 64Cu, 67Cu, 67Ga, 68Ga, 99mTc, 89Zr, 111In, 177Lu, 186Re and 225Ac, and the metal nuclide is selected from any one of Al18F, 64Cu, 67Cu, 67Ga, 68Ga, 99mTc, 89Zr, 111In, the chelating agent is selected from any one of NODAGA, NOTA2 and DOTA; linker is a connecting joint, and CHP is a collagen hybrid peptide with a polypeptide sequence of (GfO) n or (GPO) n. The probe not only has the characteristic of radiochemical marking stability, but also has the excellent biological distribution characteristics of high uptake in target organs such as tumors and low uptake in non-target organs such as liver and kidney, and has a good clinical application prospect.

A compound according to formula (I), wherein A is -As(OH) or an arsenoxide equivalent group; each of R, R, R, and R is independently selected from H, X, OH, NH, CO, SCN, -CHNH, -NHCOCH, -NHCOCHX, or NO; X is a halogen; R is -NHCHCOOH, OH, or OR; and R is C. 1-5 The present invention relates to compounds, or pharmaceutically acceptable salts, esters, prodrugs, or solvates thereof, uses of said compounds, and methods of preparing said compounds, and further relates to diagnostic methods utilizing said compounds.

In some aspects, the present disclosure pertains to a method of forming radiopaque crosslinked hydrogel particles comprising (a) mixing a reactive multi-arm polymer comprising a plurality of cyclic imide ester groups, a reactive multifunctional compound comprising a plurality of amino groups, and a radiocontrast agent under conditions in which a pH environment surrounding the reactive multi-arm polymer, the reactive multifunctional compound and the radiocontrast agent increases from an acidic pH to a basic pH, thereby forming a radiopaque hydrogel and (b) subjecting the hydrogel to a particle size reduction process, thereby forming the radiopaque crosslinked hydrogel particles. Other aspects of the present disclosure pertain to radiopaque crosslinked hydrogel particles formed from such methods, suspensions of such radiopaque crosslinked hydrogel particles, and medical supplies that contain such radiopaque crosslinked hydrogel particles.

The invention relates to exosome-coated dendrimer nanogel co-loaded with gold nanoparticles and antibiotics as well as a preparation method and application of the exosome-coated dendrimer nanogel, the dendrimer nanogel is taken as a carrier, the gold nanoparticles and drugs are co-loaded in the carrier, and the surface of the carrier is coated with exosome. The operation condition is simple, purification is easy, the bioavailability of antibiotics can be improved, targeted delivery and responsive release of the medicine at the focus position are achieved, and the good application prospect in pulmonary tuberculosis treatment is achieved.

The invention belongs to the technical field of CT imaging, and relates to a bismuth-based imaging contrast agent and a preparation method thereof. The bismuth-based imaging contrast agent is formed by chelating diethylenetriamine pentaacetic acid (DTPA) modified by sulfamic acid with bismuth ions and then connecting an antibody to the surface. The preparation method comprises the following steps: carrying out first reaction on DTPA and sulfamic acid in the presence of an activating agent to obtain sulfamic acid modified DTPA; carrying out a second reaction with an inorganic bismuth salt in a second solvent, then adjusting the pH value to be neutral, and drying to obtain aminosulfonic acid modified DTPA chelated bismuth ions; and carrying out third reaction on the DTPA chelated bismuth ions modified by sulfamic acid and an antibody, and drying to obtain the product. The CT imaging contrast agent has excellent CT imaging capability, high safety and tumor cell killing capability.

In some aspects, the present disclosure pertains to systems for forming crosslinked reaction products that comprises (a) a first composition that comprises a first multifunctional molecule that comprises a plurality of first reactive moieties that comprise azide groups and (b) a second composition that comprises a second multifunctional molecule that comprises a plurality of second reactive moieties that comprise cyclic alkyne groups, where at least one of the first and second multifunctional molecules is a reactive multi-arm polymer and where at least one of the first and second multifunctional molecules comprises an iodinated core. Other aspects of the present disclosure include crosslinked networks formed from such first and second multifunctional molecules and methods of treatment based on crosslinked networks formed from such first and second multifunctional molecules.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

In some aspects, the present disclosure pertains to systems for forming hydrogels that comprise (a) a radiopaque polyamino compound and (b) a reactive polymer comprising a plurality of hydrophilic polymer segments and a plurality of reactive moieties, wherein the reactive moieties are reactive with amino groups of the radiopaque polyamino compound, and wherein the radiopaque polyamino compound is produced by a method that comprises: (i) converting hydroxyl groups of a polyhydroxylated radiopaque compound to amino groups, (ii) converting vicinal diol groups (—CHOHCH2OH groups) of a polyhydroxylated radiopaque compound into hydroxyaminoethyl groups (—CHOHCH2NH2 groups), or (iii) converting vicinal diol groups of a polyhydroxylated radiopaque compound into aminomethyl groups (—CH2NH2 groups). In other aspects, the present disclosure pertains to hydrogels formed from such systems and to methods of treatment using such systems.

The invention is applicable to the technical field of biomedicine, and provides a preparation method and application of a multifunctional nano composite material. The material has good biocompatibility and can be used as a safe preparation for tumor treatment; the preparation is simple, green and pollution-free; the application of the quercetin in anti-tumor immunotherapy is expanded; the probe has excellent fluorescence / computed tomography dual-mode imaging performance, and can be used for determining tumor boundaries and realizing accurate treatment guidance; the nano-material has excellent photo-thermal and photo-thermal enhanced catalytic performance, has the advantages of being minimally invasive, efficient, small in toxic and side effect, controllable and the like, and can effectively treat primary, metastatic or recurrent head and neck squamous cell carcinoma by activating immunity; by inducing tumor cells to release 2 '3'-cGAMP and preventing the 2 '3'-cGAMP from being degraded, a cGAS-STING signal channel is efficiently activated, and finally the anti-tumor immune effect is enhanced.

The invention discloses a polyethylene glycol modified gold and manganese dioxide nano particle and a preparation method and application thereof, and belongs to the technical field of biological medicine, the polyethylene glycol modified gold and manganese dioxide nano particle (GMCN and PEG) has good biocompatibility under neutral physiological conditions, can relieve tumor hypoxia and increase generation of active oxygen in acidic TME, and has a good anti-tumor effect. The radiotherapy sensitivity is improved; and immune cell death is induced. Meanwhile, a cGAS-STING signal channel can be activated, dendritic cell maturation, macrophage M1 polarization and T cell infiltration are promoted, and the immunosuppression state in TME is counteracted. In addition, the GMCN-coated PEG also has an MR-CT bimodal imaging enhancement function, and integration of diagnosis and treatment is realized. The nano sensitizer disclosed by the invention has huge potential in the aspects of improving the radiotherapy curative effect, remodeling the tumor microenvironment, promoting the anti-tumor immunity, enhancing the biomedical imaging and the like.

The invention belongs to the technical field of radiotherapy sensitizers, and relates to a hafnium-titanium composite nano radiosensitizer as well as a preparation method and application thereof. The invention discloses a preparation method of a hafnium-titanium composite nano radiosensitizer, which comprises the following steps: (1) mixing a titanium-based metal frame compound Ti-MOF and hafnium-based oxide HfO2 with water according to a mass ratio of 2: 1-1: 2, putting the mixture into a reaction kettle, and carrying out hydrothermal reaction at 80-130 DEG C for 6-48 hours to obtain hafnium-titanium nanoparticles; and (2) dispersing the hafnium-titanium nanoparticles in the hydrophilic modification material solution, and stirring at room temperature for 6-48 hours to obtain the hafnium-titanium composite nano radiosensitizer. The invention also discloses application of the hafnium-titanium composite nano radiosensitizer in the field of imaging and preparation of medicines for treating colorectal cancer.

The invention provides a developable hydrogel. The developable hydrogel comprises a first component and a second component, the first component is maleimide group end capped multi-arm polyethylene glycol; and the second component is a sulfydryl modified iodine-containing contrast agent. The components of the hydrogel can be prepared into a neutral solution, the reaction is mild in a physiological environment, the safety is high, and the formed hydrogel is good in biocompatibility. The hydrogel disclosed by the invention does not cause a hypertonic phenomenon in vivo, and the degraded hydrophilic iodine molecule unit is easy to metabolize and exclude from the body. The use concentration of the two components of the hydrogel is low, the raw material concentration is greatly reduced, the use amount is reduced, the cost can be reduced, and the hydrogel is more friendly to a human body and has better clinical safety. The hydrogel provided by the invention can realize accurate adjustment of a wide gelation time window of 2-120s, the development value can be quantitatively regulated and controlled within 80-400Hu, the hydrogel is adaptive to application requirements of different tissues, and the degradation period of the hydrogel in vivo can be adjusted within 1-24 weeks.

This disclosure relates to recombinant adeno-associated virus (rAAV) delivery of ceroid lipofuscinosis neuron 3 (CLN3) polynucleotides. This disclosure provides rAAV and methods of using rAAV for CLN3 gene therapy of neuronal ceroid lipofuscinosis or CLN3-Batten disease.